Abstract
A large number of interactions with anti-epileptic drugs have been reported, although only a proportion of these are of real and documented clinical significance. A particularly important group of interactions is represented by those resulting in inhibition of anti-epileptic drug metabolism, with the attendant risk of precipitating clinical signs of intoxication. Examples include the inhibition of phenytoin metabolism by sulthiame and isoniazid, the inhibition of carbamazepine metabolism by propoxyphene and the inhibition of phenobarbital metabolism by valproic acid. Plasma protein-binding interactions are unlikely to cause a long-lasting alteration in the response to anticonvulsant drugs, but they are important because they change the relationship between total serum drug levels and pharmacological effect. Phenytoin, phenobarbital, primidone, and carbamazepine are potent inducers of the hepatic drug-metabolizing microsomal enzymes. This may result in an enhanced rate of metabolism and reduced effectiveness of a number of other drugs, including steroid oral contraceptives, oral anticoagulants, quinidine, vitamin D, prednisone, dexamethasone and metyrapone.
| Original language | English |
|---|---|
| Pages (from-to) | 95-100 |
| Number of pages | 6 |
| Journal | International Journal of Clinical Pharmacology Research |
| Volume | 2 |
| Issue number | 4 Suppl. 1 |
| Publication status | Published - 1982 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Pharmacokinetic interactions with anti-epileptic drugs. / Gatti, G.; Perucca, E.; Lecchini, S.
In: International Journal of Clinical Pharmacology Research, Vol. 2, No. 4 Suppl. 1, 1982, p. 95-100.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetic interactions with anti-epileptic drugs
AU - Gatti, G.
AU - Perucca, E.
AU - Lecchini, S.
PY - 1982
Y1 - 1982
N2 - A large number of interactions with anti-epileptic drugs have been reported, although only a proportion of these are of real and documented clinical significance. A particularly important group of interactions is represented by those resulting in inhibition of anti-epileptic drug metabolism, with the attendant risk of precipitating clinical signs of intoxication. Examples include the inhibition of phenytoin metabolism by sulthiame and isoniazid, the inhibition of carbamazepine metabolism by propoxyphene and the inhibition of phenobarbital metabolism by valproic acid. Plasma protein-binding interactions are unlikely to cause a long-lasting alteration in the response to anticonvulsant drugs, but they are important because they change the relationship between total serum drug levels and pharmacological effect. Phenytoin, phenobarbital, primidone, and carbamazepine are potent inducers of the hepatic drug-metabolizing microsomal enzymes. This may result in an enhanced rate of metabolism and reduced effectiveness of a number of other drugs, including steroid oral contraceptives, oral anticoagulants, quinidine, vitamin D, prednisone, dexamethasone and metyrapone.
AB - A large number of interactions with anti-epileptic drugs have been reported, although only a proportion of these are of real and documented clinical significance. A particularly important group of interactions is represented by those resulting in inhibition of anti-epileptic drug metabolism, with the attendant risk of precipitating clinical signs of intoxication. Examples include the inhibition of phenytoin metabolism by sulthiame and isoniazid, the inhibition of carbamazepine metabolism by propoxyphene and the inhibition of phenobarbital metabolism by valproic acid. Plasma protein-binding interactions are unlikely to cause a long-lasting alteration in the response to anticonvulsant drugs, but they are important because they change the relationship between total serum drug levels and pharmacological effect. Phenytoin, phenobarbital, primidone, and carbamazepine are potent inducers of the hepatic drug-metabolizing microsomal enzymes. This may result in an enhanced rate of metabolism and reduced effectiveness of a number of other drugs, including steroid oral contraceptives, oral anticoagulants, quinidine, vitamin D, prednisone, dexamethasone and metyrapone.
UR - http://www.scopus.com/inward/record.url?scp=0020314568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020314568&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0020314568
VL - 2
SP - 95
EP - 100
JO - International Journal of Clinical Pharmacology Research
JF - International Journal of Clinical Pharmacology Research
SN - 0251-1649
IS - 4 Suppl. 1
ER -